Kenvue Inc. (NYSE:KVUE) Holdings Reduced by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 93.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,743 shares of the company’s stock after selling 1,318,066 shares during the period. Brandywine Global Investment Management LLC’s holdings in Kenvue were worth $1,873,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Paloma Partners Management Co bought a new stake in Kenvue during the 3rd quarter valued at $360,000. Benjamin Edwards Inc. bought a new stake in shares of Kenvue during the third quarter valued at about $1,323,000. Hilltop Holdings Inc. raised its stake in shares of Kenvue by 3.1% during the third quarter. Hilltop Holdings Inc. now owns 80,331 shares of the company’s stock valued at $1,858,000 after purchasing an additional 2,434 shares in the last quarter. Janus Henderson Group PLC grew its position in Kenvue by 40.6% in the 3rd quarter. Janus Henderson Group PLC now owns 219,576 shares of the company’s stock valued at $5,080,000 after buying an additional 63,400 shares in the last quarter. Finally, Investment Management Corp of Ontario increased its stake in Kenvue by 48.9% during the 3rd quarter. Investment Management Corp of Ontario now owns 63,627 shares of the company’s stock valued at $1,472,000 after buying an additional 20,900 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 0.0 %

Shares of NYSE:KVUE opened at $23.87 on Thursday. The firm has a 50 day simple moving average of $22.50 and a 200 day simple moving average of $22.47. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $45.62 billion, a PE ratio of 45.04, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. Kenvue’s dividend payout ratio is 154.72%.

Analysts Set New Price Targets

Several research firms have recently issued reports on KVUE. Barclays increased their price objective on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Thursday, March 27th. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price target for the company. Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.